Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

PURPOSE: To investigate quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in a post hoc exploratory analysis of the phase III ARIEL3 study of rucaparib maintenance treatment versus placebo. PATIENTS AND METHODS: Patients with platinu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Gancedo, Margarita Amenedo, Fong, Peter C., Goh, Jeffrey C., O’Malley, David M., Armstrong, Deborah K., Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M., Cella, David, Meunier, Juliette, Goble, Sandra, Cameron, Terri, Maloney, Lara, Mörk, Ann-Christin, Bedel, Josh, Ledermann, Jonathan A., Coleman, Robert L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2020
Konular:
RAPID COMMUNICATIONS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7571791/
https://ncbi.nlm.nih.gov/pubmed/32840418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.03107
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller